Get started
Work

CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Year: 2018
Type: article
Abstract: Background: Combining PD-1 and CTLA-4 inhibitors can augment antitumor immune responses. In the phase 1 CheckMate 012 study, first-line nivo (anti–PD-1 antibody) plus ipi (anti–CTLA-4 antibody) exhibited a higher objective response rate (ORR) and 2-year overall survival (OS) rate than nivo alone in pts with stage IIIB/IV NSCLC. Pts whose tumors expressed PD-L1 or had a high tumor mutational burden (TMB) showed better outcomes. High TMB was identified in the phase 2 CheckMate 568 (nivo + ipi) and phase 3 CheckMate 026 (nivo alone) studies and validated in phase 3 CheckMate 227 (nivo + ipi) as a potential predictive biomarker, independent of PD-L1 expression.
DOI: 10.1093/annonc/mdy292.124
Authors: S. Gettinger, T. Beck, X. Yang, B. Telivala, D. Morgensztern, V. Velcheti, S.S. Ramalingam, K. Schalper, M. Dajee, A. Ranck, R. Yang, D.R. Spigel
Institutions: Yale Cancer Center, Yale University, Highlands Oncology Group, Washington University in St. Louis, Cleveland Clinic, Emory University, Winship Cancer Institute, Bristol-Myers Squibb (United States), Sarah Cannon, Tennessee Oncology
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2895844613
FWCI: 0.169
Cites:
Cited by: 2
Related to: 10